SCHEMBL1009221

SCHEMBL1009221

CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC1OC1(C)C

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LSS P48449 11/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401906 1.00 LSS (0.78) LSS
SCHEMBL1142772 1.00 LSS (0.78) LSS
SCHEMBL188732 1.00 LSS (0.78) LSS
SCHEMBL29711771 0.94 LSS (0.83) LSS
SCHEMBL29711785 0.94 LSS (0.83) LSS
SCHEMBL2833064 0.90 LSS (0.66) LSS
SCHEMBL4583832 0.89 LSS (0.65) LSS
SCHEMBL4583833 0.89 LSS (0.65) LSS
SCHEMBL25205292 0.86 LSS (0.71) LSS
SCHEMBL10048472 0.86 LSS (0.71) LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139286-A1 MICROBIAL PRODUCTION OF TRITERPENOIDS INCLUDING MOGROSIDES MANUS BIO INC (US) 2026-05-21 US claimed
EP-3877519-B1 BIOSYNTHESIS OF MOGROSIDES GINKGO BIOWORKS INC (US) 2026-03-11 EP claimed
US-12570991-B2 Recombinant yeast strain having sterol productivity, preparation method therefor and use thereof DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2026-03-10 US claimed
EP-4698673-A1 STRAINS AND METHODS FOR THE PRODUCTION OF MOGROSIDES DSM IP Assets B.V. (NL) 2026-02-25 EP claimed
US-20250346914-A1 SAPONARIOSIDE BIOSYNTHETIC ENZYMES PLANT BIOSCIENCE LTD (GB) 2025-11-13 US claimed
EP-3399041-B1 ENHANCEMENT OF GINSENOSIDE PRODUCTION BY IMPROVEMENT OF YEAST CELL ORGANELLE KOREA RES INST CHEMICAL TECH (KR) 2025-10-22 EP claimed
US-12404516-B2 Method to obtain low triterpene/triterpenoid-containing natural rubber latex FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2025-09-02 US claimed
US-12391963-B2 Metabolic engineering PLANT BIOSCIENCE LIMITED (GB) 2025-08-19 US claimed
WO-2025101625-A1 ENZYMES, HOST CELLS, AND METHODS FOR PRODUCING MOGROSIDES MANUS BIO INC. (US) 2025-05-15 WO claimed
EP-4547833-A1 SAPONARIOSIDE BIOSYNTHETIC ENZYMES Plant Bioscience Limited (GB) 2025-05-07 EP claimed
US-20070016982-A1 Transgenic plants with increased titerpene saponin levels E. I. DU PONT DE NEMOURS AND COMPANY 2007-01-18 US claimed
US-20050222071-A1 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) L'OREAL (FR) 2005-10-06 US claimed
EP-1499177-A4 TRANSGENIC PLANTS WITH A SUPPRESSED TRITERPENE LEVEL DU PONT (US) 2005-09-21 EP claimed
EP-1513482-A2 TOPICAL USE OF AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DS RNA) L'OREAL (FR) 2005-03-16 EP claimed
EP-1499177-A2 TRANSGENIC PLANTS WITH A SUPPRESSED TRITERPENE LEVEL E.I. DU PONT DE NEMOURS AND COMPANY (US) 2005-01-26 EP claimed
US-6747056-B2 STREPTOMYCES HAS ABILITY TO PRODUCE K99- 5041-C1X, INHIBITORY ACTIVITY AGAINST LANOSTEROL SYNTHASE, PREVENTIVE AND THERAPEUTIC AGENTS CAUSED BY ACCUMULATION OF CHOLESTEROL IN HUMANS AND ANTIFUNGAL AGENTS. THE KITASATO INSTITUTE (JP) 2004-06-08 US claimed
US-20040010818-A1 Use of recombinant DNA fragments encoding at least a portion of an oxidosqualene cyclase to lower the level of a triterpene in plants and seeds; method for reducing saponin level in a transgenic soybean plant MCGONIGLE BRIAN (US) 2004-01-15 US claimed
US-20040002533-A1 Novel K99-5041 substance and production thereof THE KITASATO INSTITUTE (JP) 2004-01-01 US claimed
WO-2003101376-A2 TOPICAL USE OF AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DS RNA) L'OREAL (FR) 2003-12-11 WO claimed
WO-2003095615-A2 TRANSGENIC PLANTS WITH A SUPPRESSED TRITERPENE LEVEL E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-11-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002533-A1 Novel K99-5041 substance and production thereof CYP51A1, LSS, CYP46A1 LSS 2/4885
US-20050222071-A1 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) DCLRE1B, POLRMT, ADAR LSS 4041/4885
US-20260139286-A1 MICROBIAL PRODUCTION OF TRITERPENOIDS INCLUDING MOGROSIDES POR, GALE, CYP51A1 LSS 31/4885
US-12570991-B2 Recombinant yeast strain having sterol productivity, preparation method therefor and use thereof ERG28, CYP46A1, CYP51A1 LSS 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.